Cargando…

Farnesyl pyrophosphate synthase inhibitor, ibandronate, improves endothelial function in spontaneously hypertensive rats

Reactive oxygen species (ROS), originating predominantly from vascular smooth muscle cells (VSMCs), lead to vascular damage and endothelial dysfunction in rats with hypertension. The downstream signaling pathways of farnesyl pyrophosphate (FPP) synthase, Ras-related C3 botulinum toxin substrate 1 (R...

Descripción completa

Detalles Bibliográficos
Autores principales: HAN, JIE, JIANG, DONG-MEI, YE, YANG, DU, CHANG-QING, YANG, JIAN, HU, SHEN-JIANG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838142/
https://www.ncbi.nlm.nih.gov/pubmed/27035426
http://dx.doi.org/10.3892/mmr.2016.5025
_version_ 1782427942702284800
author HAN, JIE
JIANG, DONG-MEI
YE, YANG
DU, CHANG-QING
YANG, JIAN
HU, SHEN-JIANG
author_facet HAN, JIE
JIANG, DONG-MEI
YE, YANG
DU, CHANG-QING
YANG, JIAN
HU, SHEN-JIANG
author_sort HAN, JIE
collection PubMed
description Reactive oxygen species (ROS), originating predominantly from vascular smooth muscle cells (VSMCs), lead to vascular damage and endothelial dysfunction in rats with hypertension. The downstream signaling pathways of farnesyl pyrophosphate (FPP) synthase, Ras-related C3 botulinum toxin substrate 1 (Rac1) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, mediate the generation of ROS. The present study investigated the effect of the FPP synthase inhibitor, ibandronate, on ROS production, the possible beneficial effect on endothelial dysfunction and the underlying mechanisms in spontaneously hypertensive rats (SHRs). The SHRs were treated with ibandronate for 30 days. Endothelium-dependent and independent vasorelaxation were measured in isolated aortic rings. Additionally, VSMCs from the SHRs and Wistar-Kyoto (WKY) rats were cultured. The production of ROS and activation of NADPH oxidase were determined using fluorescence and chemiluminescence, respectively, in vivo and in vitro. Angiotensin II (Ang II) increased ROS production in the cultured VSMCs from the WKY rats and SHRs, in a concentration-dependent manner. The Ang II-induced responses were more marked in the SHR VSMCs, compare with those in the WKY VSMCs, however, the response decreased significantly following ibandronate pretreatment. Treatment with ibandronate significantly decreased the production of ROS, translocation of NADPH oxidase subunit p47phox, and activities of NADPH oxidase and Rac1 in the aorta and VSMCs, and improved the impaired endothelium-dependent vasodilation in the SHRs. Adding geranylgeraniol, but not farnesol or mevalonate, reversed the inhibitory effects of ibandronate. In addition, inhibiting geranylgeranyl-transferase mimicked the effect of ibandronate on the excess oxidative response. Ibandronate exerted cellular antioxidant effects through the Rac1/NADPH oxidase pathway. These effects may have contributed to the vasoprotective effects on the impaired endothelium in SHRs.
format Online
Article
Text
id pubmed-4838142
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-48381422016-04-21 Farnesyl pyrophosphate synthase inhibitor, ibandronate, improves endothelial function in spontaneously hypertensive rats HAN, JIE JIANG, DONG-MEI YE, YANG DU, CHANG-QING YANG, JIAN HU, SHEN-JIANG Mol Med Rep Articles Reactive oxygen species (ROS), originating predominantly from vascular smooth muscle cells (VSMCs), lead to vascular damage and endothelial dysfunction in rats with hypertension. The downstream signaling pathways of farnesyl pyrophosphate (FPP) synthase, Ras-related C3 botulinum toxin substrate 1 (Rac1) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, mediate the generation of ROS. The present study investigated the effect of the FPP synthase inhibitor, ibandronate, on ROS production, the possible beneficial effect on endothelial dysfunction and the underlying mechanisms in spontaneously hypertensive rats (SHRs). The SHRs were treated with ibandronate for 30 days. Endothelium-dependent and independent vasorelaxation were measured in isolated aortic rings. Additionally, VSMCs from the SHRs and Wistar-Kyoto (WKY) rats were cultured. The production of ROS and activation of NADPH oxidase were determined using fluorescence and chemiluminescence, respectively, in vivo and in vitro. Angiotensin II (Ang II) increased ROS production in the cultured VSMCs from the WKY rats and SHRs, in a concentration-dependent manner. The Ang II-induced responses were more marked in the SHR VSMCs, compare with those in the WKY VSMCs, however, the response decreased significantly following ibandronate pretreatment. Treatment with ibandronate significantly decreased the production of ROS, translocation of NADPH oxidase subunit p47phox, and activities of NADPH oxidase and Rac1 in the aorta and VSMCs, and improved the impaired endothelium-dependent vasodilation in the SHRs. Adding geranylgeraniol, but not farnesol or mevalonate, reversed the inhibitory effects of ibandronate. In addition, inhibiting geranylgeranyl-transferase mimicked the effect of ibandronate on the excess oxidative response. Ibandronate exerted cellular antioxidant effects through the Rac1/NADPH oxidase pathway. These effects may have contributed to the vasoprotective effects on the impaired endothelium in SHRs. D.A. Spandidos 2016-05 2016-03-21 /pmc/articles/PMC4838142/ /pubmed/27035426 http://dx.doi.org/10.3892/mmr.2016.5025 Text en Copyright: © Han et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
HAN, JIE
JIANG, DONG-MEI
YE, YANG
DU, CHANG-QING
YANG, JIAN
HU, SHEN-JIANG
Farnesyl pyrophosphate synthase inhibitor, ibandronate, improves endothelial function in spontaneously hypertensive rats
title Farnesyl pyrophosphate synthase inhibitor, ibandronate, improves endothelial function in spontaneously hypertensive rats
title_full Farnesyl pyrophosphate synthase inhibitor, ibandronate, improves endothelial function in spontaneously hypertensive rats
title_fullStr Farnesyl pyrophosphate synthase inhibitor, ibandronate, improves endothelial function in spontaneously hypertensive rats
title_full_unstemmed Farnesyl pyrophosphate synthase inhibitor, ibandronate, improves endothelial function in spontaneously hypertensive rats
title_short Farnesyl pyrophosphate synthase inhibitor, ibandronate, improves endothelial function in spontaneously hypertensive rats
title_sort farnesyl pyrophosphate synthase inhibitor, ibandronate, improves endothelial function in spontaneously hypertensive rats
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838142/
https://www.ncbi.nlm.nih.gov/pubmed/27035426
http://dx.doi.org/10.3892/mmr.2016.5025
work_keys_str_mv AT hanjie farnesylpyrophosphatesynthaseinhibitoribandronateimprovesendothelialfunctioninspontaneouslyhypertensiverats
AT jiangdongmei farnesylpyrophosphatesynthaseinhibitoribandronateimprovesendothelialfunctioninspontaneouslyhypertensiverats
AT yeyang farnesylpyrophosphatesynthaseinhibitoribandronateimprovesendothelialfunctioninspontaneouslyhypertensiverats
AT duchangqing farnesylpyrophosphatesynthaseinhibitoribandronateimprovesendothelialfunctioninspontaneouslyhypertensiverats
AT yangjian farnesylpyrophosphatesynthaseinhibitoribandronateimprovesendothelialfunctioninspontaneouslyhypertensiverats
AT hushenjiang farnesylpyrophosphatesynthaseinhibitoribandronateimprovesendothelialfunctioninspontaneouslyhypertensiverats